Le Lézard
Classified in: Health
Subject: FDA

Breckenridge Announces Final Approval of its ANDA for Exemestane Tablets (Aromasin®)

BOCA RATON, Fla., Feb. 27, 2019 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today that the U.S. Food and Drug Administration has granted final approval for its Abbreviated New Drug Application for Exemestane Tablets, 25mg, generic for Aromasin® Tablets by Pfizer.  Breckenridge's Exemestane Tablets product was developed in collaboration with Medikl Ltd. and MSN Laboratories Private Ltd.  MSN will manufacture and supply the product from its facilities in Hyderabad, India.  Additional announcements will be made prior to product launch. Exemestane Tablets generated annual sales of $65 million during the twelve months ending December 31, 2018, according to industry sales data.

About Breckenridge:
Breckenridge Pharmaceutical, Inc. is a privately held own-label distributor that performs pharmaceutical marketing, research and development, as well as marketing and distribution in the U.S. The company was founded in 1983 and markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by wholesalers, distributors, chains, and managed care accounts, as well as retail pharmacies nationwide. The company markets over 70 products in a variety of dosage forms, including: tablets, capsules, liquids, suspensions, ophthalmics, nasal sprays, powders and injectable products.

About Medikl:
MEDIKL is a privately held pharmaceutical company founded in 2009. MEDIKL is committed to the development of a premium range of generic pharmaceutical products in a variety of dosage forms, including: tablets, capsules, liquids and injectable products. The company has a multi-product agreement with Breckenridge for marketing its products in the U.S., with five additional products expected to be launched in the following two years.

About MSN:
MSN Group (MSN) is the fastest growing research-based pharmaceutical company out of India. Founded in 2003 with a mission to make health care affordable, MSN has nine API (including Oncology) and five finished dosage facilities, established across Hyderabad and in the U.S.  The group has an integrated R&D Center for both API and formulation under one roof, dedicated to research and development of pharmaceutical products to make them more accessible.  With a core focus on speed and consistency in delivery, MSN has won the trust of more than 350 customers across 65 countries around the globe, including the U.S., Europe, Latin America, Middle East, Asia-Pacific, Africa and CIS markets. MSN's product basket offers over 250 APIs and 120 formulations covering 35 major therapies.

SOURCE Breckenridge Pharmaceutical, Inc.

These press releases may also interest you

at 14:40
Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively "HDF"), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. ("Enzo" or the "Company"), today announced that Egan-Jones Proxy...

at 14:38
Chairman and CEO, Jeffrey M. Stamps, R.Ph., of Baltimore-based  Remedi SeniorCare, announces the opening of the company's newest PAXIT® pharmacy in Chicago, Illinois.  With the opening of its twelfth location, Remedi SeniorCare is licensed in 32...

at 14:33
As we have emphasized, the FAA and other global regulators will determine when the 737 MAX returns to service. However, in order to help our customers and suppliers plan their operations, we periodically provide them with our best estimate of when...

at 14:25
VerdePharmHealth and Base One Health today announced a national group purchasing agreement for procurement of cannabis products across the multi-specialty network. Both organizations aim to simplify the supply chain, lower costs, and provide broad...

at 14:15
The global cardiovascular devices market is expected to reach US$ 71.1 Bn in 2027 from US$ 40.8 Bn in 2018. The cardiovascular devices market is estimated to grow with a CAGR of 6.5% from 2019-2027. Read the full report:...

at 14:10
Atlantic Health System's Morristown Medical Center, nationally recognized for heart care, today opened the second of two new 36-bed units for patients with heart disease, completing a two-story expansion of the Gagnon Cardiovascular Institute....

News published on 27 february 2019 at 10:00 and distributed by: